PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Eli Lilly (NYSE:LLY) shares reached a new 52-week low on Thursday as concerns over late-stage trial data for the company’s ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

Subcutaneous amycretin phase 1 b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare ...

Amycretin effectively combines the functionality of two different drugs into a single molecule that targets two hormones involved in regulating hunger and blood sugar levels: GLP-1 and amylin.

People taking amycretin lost 13 per cent of their weight in this period, Novo Nordisk announced today, according to a report by Reuters. Those taking placebo pills lost 1 per cent.

The results show that amycretin led to “remarkable reductions in body weight over only 12 weeks,” the research team led by Agnes Gasoirek, a senior clinical pharmacology specialist at Novo ...

Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in ...